[1] Bjorklund A,Lindvall O.Cell replacement therapies for central nervous system disorders[J].Nature Neurosci,2000,3(6):537-544.
[2] Lindvall O,Rehncrona S,Gustuvii B,et al.Fetal dopamine-richmesencephalic grafts in parkinson' disease[J].Lancet,1988,2(8626-8627):1483-1484.
[3] Mckay R.Enhance proliferation,survival,and dopaminergic differentiation of CNS precursors in lowered oxygen[J].J Neurosci,2000,20(19):7377-7384.
[4] Mckay R.Stem cell-hype and hope[J].Nature,2000,406(6794):361-364.
[5] Studer L,Ta:ar V,Mckay RDG.Transplantation of expended mesencephalic precursors leads to recovery in parkinsonina rats[J].Nature Neurosci,1998,1(4):290-295.
[6] Haque NS,LeBlanc CJ,Jsacson 0.Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum:y a su:set of aldehyde dehydrogenase-postive TH neurons[J].Cell Transplant,1997,6(3):239-248.
[7] Poewe W,Scherfler C.Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice[J].Mov Disorde,2003,18(7):16-21.
[8] Remy P,Samson Y,Hantraye P,et al.Clinical 18F-fluorodopa uptake in five grafted parkinsonian patients[J].Ann Neurol,1995,38(4):580-588.
[9] Kuwabara H,Reith J.Human striatal L-dopa decar:oxylase activity estimate in vivo using 6-[18F] fluorodopa and positron emis-sion to-mography:error analysis and application to normal subjects[J]. J Cereb Blood Flow Metab,1993,13(1):43-56.
[10] Snow BJ,Tooyama I,McGeer EG,et al.Human positron emission tomographic[18F] fluorodopa studies correlate with dopamine cell counts and levels[J].Ann neurol,1993,34(3):324-330.
[11] Kordower JH,Rosenstein JM,Collier TJ,et al.Functional fetal nigral in a patient with Parkinson's disease:chemoanatomic,ultra-structural,and metabolic studies[J].J Comp Neural,1996,370(2):203-230.
[12] Pate BD,Kawamata T,Yamada T,et al.Correlate of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices[J].Ann Neurol,1993,34(3):331-338.
[13] Yee RE,Huang SC,Stour DB,et al.Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys:in vivo and in vitro investigation[J].J Neurochem,2000,74(3):1147-1157.
[14] Freed CR.Transplantation of embryonic dopamine neurons for severe Parkinson's disease[J].New Engl J Med,2001,344(10):710-719.
[15] Cochen V,Ribeiro MJ,Nguyen JP.Transplantation in parkinson's disease:PET changes correlate with the amount of grafted tissue[J].Mov Disorde,2003,18(8):928-932.
[16] Ribeiro MJ,Vaughan RA,Loćh C,et al.Dopaminergic function and dopamine transporter density assessed with PET in parkinson's disease[J].Arch Neural,2002,59(4):580-586.
[17] Wenning GK,Odin P,Morrish P,et al.Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease[J].Ann Neurol,1997,42(1):95-107.
[18] Bjorklund A.Dopaminergic transplants in experimental parkinsonism:Cellular mechamisms of graft-induced functional recovery[J].Curr Opin Neurobiol,1992,2(5):683-689.
[19] Schumacher JM,Ellias SA,Palmer EP,et al.transplantation of embryonic porcinemesencephalic tissue in patients with PD[J].Neurol,2000,54(5):1042-1050.